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Influenza and Pneumococcal
Vaccination Demand Responses to
Changes in Infectious Disease Mortality
Ying-Chun Li, Edward C. Norton, and William H. Dow
Objective. To test the hypothesis that individuals are more likely to receive a
vaccination against influenza or pneumonia as the perceived disease threat increases.
Data Sources. This study uses two different national datasets. Individual-level
information about the vaccination rates of 38,768 elderly persons are from the
Behavioral Risk Factor Surveillance System, 1993–1998. Information on the combined
influenza and pneumonia state mortality rates are measured from the Compressed
Mortality File.
Study Design. Using both cross-sectional and state fixed-effects panel data estimators,
we model an individual’s probability of having an influenza or pneumococcal
vaccination as a function of the lagged state mortality rate. Multiyear lags are specified
in order to estimate the duration of the effect of disease mortality on individual
vaccination behavior.
Principal Findings. Results support our hypothesis that influenza vaccination
behavior responds positively to disease mortality, even after a one-year lag. We further
find that cross-sectional estimators used in previous work yield downward-biased
estimates, although even for our preferred panel data models, the estimated effects are
small.
Conclusions. The findings indicate that behavioral demand responses can help to
limit infectious disease epidemics, and suggest further research onhowpublic awareness
campaigns can mediate this disease threat responsiveness behavior.
Key Words. Vaccination, influenza, pneumonia, mortality
Pneumonia and influenza are infectious diseases with severe health
consequences for the general population, and for the elderly in particular.
Based on recent reports from the Centers for Disease Control and Prevention
(CDC), pneumonia and influenza are still the sixth leading cause of deaths for
the general population and the fifth leading cause of deaths for elderly persons
in the United States. Among total deaths due to pneumonia and influenza,
about 90 percent are elderly persons (Hoyert, Kochanek, and Murphy 1999;
Janes et al. 1999; Murphy 2000; Hoyert et al. 2001; Anderson 2002). In
addition, approximately 48,000 of the pneumonia and influenza hospitaliza-
tions per year occur among elderly persons who are at highest risk for
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influenza-related complications (Centers for Disease Control and Prevention
2000). The risk of being hospitalized due to pneumonia and influenza
increases two- to threefold when a person aged 65 years or older has one or
more chronic diseases (Honkanen, Keistinen, and Kivelä 1997). Medicare
costs for influenza-related hospitalizations can reach one billion dollars each
year (Fedson 1994; Houck, Lowery, and Prela 1997).
Clinical preventive services can reduce morbidity and mortality.
Influenza immunization is associated with fewer hospitalizations and lower
risk of death for both pneumonia and influenza during the influenza season. It
is also associated with fewer outpatient visits for pneumonia and influenza and
all respiratory conditions (Nichol, Baken, and Nelson 1999). Influenza and
pneumococcal immunizations are cost-effective (Fedson 1994; Sisk et al. 1997;
Finger and Francis 1998).
Despite recommendations from national organizations and scientific
evidence for their effectiveness, vaccination rates remain low. The Advisory
Committee on Immunization Practices recommends that persons aged 65 or
older receive annual influenza immunization and at least one lifetime dose of
pneumococcal immunization (Houck, Lowery, and Prela 1997). The
American College of Physicians suggests that persons who received
pneumococcal vaccine before age 65 be reimmunized at 65 if more than six
years have passed since the initial vaccine (Goldberg andChavin 1997). In this
study we investigate the determinants of vaccine demand by elderly persons.
In particular, we test the hypothesis that individual vaccine demand is partly
determined by the perceived seriousness of the influenza and pneumonia
threat (Philipson 2000).
Testing the empirical validity of this threat-responsiveness hypothesis is
important both for understanding the limitations of access-related interven-
tions aimed at increasing vaccination levels during nonepidemic periods, and
for understanding the potential power of public information campaigns in
helping to raise vaccination levels during epidemics. The hypothesis has been
supported by tests in a handful of populations with different diseases,
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including HIV prevention for young men (Ahituv, Hotz, and Philipson 1996),
measles immunization for children (Philipson 1996; Goldstein et al. 1996),
and influenza vaccinations for working age and elderly persons (Mullahy
1999).
In addition to further testing the hypothesis in a different setting, our
paper contributes to this literature in two other ways. First, in contrast to
previous work examining influenza vaccination behavior, we control for a
variety of potentially unobserved confounding variables through the use of
panel data techniques. If persistently higher disease prevalence areas always
have higher vaccination rates for systemic reasons, then cross-sectional
approaches may yield upwardly biased estimates of short-run behavioral
responses to epidemics. Or conversely, if some areas have persistently low
demand for vaccination due to unobserved factors such as regional access to
care, then the low demand would endogenously cause persistently high
disease prevalence, implying that the cross-sectional approaches could
underestimate the true threat-responsiveness.
A second contribution of our work is to further examine the role of
perceptions in affecting threat-responsiveness behavior. The theory as
presented by Philipson (2000) predicts that rational and well-informed
individuals will respond to current infectious disease threats by demanding
efficacious vaccines. We test this prediction in two ways. First, because the
pneumococcal vaccine is not considered efficacious against the form of
pneumonia that increases during influenza epidemics, the theory would
predict that increased threats should lead to increased influenza vaccination,
but not increased pneumococcal vaccination. If pneumococcal vaccination
also responds, this would be indirect evidence consistent with the role of
misperceptions in affecting vaccination demand. The second way in which we
test the role of perceptions is by examining responsiveness to past threats, as
opposed to Philipson’s tests of responsiveness to current threats. Given that the
rapid mutation of influenza viruses causes there to be little relationship
between epidemic levels from one year to the next, the canonical theory
predicts zero responsiveness to the previous year’s influenza disease threats.
This prediction is at odds, however, with the responsiveness found byMullahy
(1999) to the previous year’s influenza epidemic level. Mullahy hypothesizes
that lagged prevalence could affect behavior by changing subjective
expectations of the probability and severity of infection. We estimate disease
threat-responsiveness for one-, two-, and three-year prevalence lags, in order
to better test Mullahy’s hypothesis against omitted variables explanations, and
to better understand the duration of such perception effects on behavior.
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CONCEPTUAL FRAMEWORK
The demand for vaccinations depends on the perceived costs and benefits of
the vaccinations, under uncertainty (Mullahy 1999). Part of the uncertainty
comes from not knowing whether the individual will be infected——with or
without the vaccine——and if infected, then for how long and at what severity.
People will be more likely to get vaccinated if they think they will get the
disease, and if they think the vaccine will be effective.
In terms of cost, Medicare now provides free influenza and pneumo-
coccal vaccines for elderly persons. Free Medicare coverage was extended to
pneumococcal vaccines in 1981 and to influenza vaccines in 1993
(Carrasquillo, Lantigua, and Shea 2001). However, free vaccines are not
sufficient to ensure a high vaccination rate (Honkanen, Keistinen, and Kivelä
1997; Rhodes, Arday, and Arday 1997). One CDC study indicated that in
1997, 65.5 percent of elderly persons reported receiving an influenza
vaccination during the preceding year and 45.4 percent of elderly have ever
had a pneumococcal vaccination, but with great variations across states
(Centers for Disease Control and Prevention 1998). Even with no out-of-
pocket cost for the vaccine itself, individuals still face a time cost and office visit
copayment when getting vaccinated. The time cost is lower for those who live
close to their physician, have frequent interaction with the medical care
system, are retired, and live in an area with frequent public vaccination days.
Socioeconomic status and local health care markets may also affect demand
via the time cost.
The benefits of vaccination arise from improved health status. A variety
of individual characteristics may affect these benefits. For example, those in
poor health status, especially those with weak pulmonary systems (such as
smokers), may demand vaccinations because of greater susceptibility to
disease. Socioeconomic variables and local health care markets may also
influence demand via this health status pathway, by affecting both the actual
and perceived benefits of vaccination.
Of particular interest for our analysis, we hypothesize that vaccination
demand depends positively on the contemporaneous disease threat, because
the benefits of vaccination are greater when the chance of catching the disease
is higher. Philipson (2000) defines the infection elasticity for vaccine-preventable
diseases to be the increase in the vaccination rate induced by each increase in
the infection rate. While biological epidemiology assumes that this elasticity is
zero, meaning no behavioral response, the threat-responsiveness hypothesis
recognizes that individuals change their behavior when disease threat rises. As
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the probability of infection rises, a person will be more likely to take
preventive action. For example, to prevent influenza, a person might get
vaccinated, avoid contact with other infected persons, dress warmly, and eat
a healthy diet.
Health belief models also predict that individual perceptions of suscept-
ibility to disease and severity of disease affect the probability of taking
preventive action (Rosenstock 1966; Becker, Drachman, and Kirscht 1974),
but they consider a wider range of influences on such perceptions besides the
objective risk. Following this literature, as well as Mullahy (1999), we
hypothesize that perceptions of the current disease prevalence and severity
may be influenced by the lagged disease threat. These perceptions may be
formed via a variety of pathways, such as recent infectious experiences
by individuals and their acquaintances, recollection of information from
their physician or media reports from CDC surveillance. The extent to which
this lagged disease threat actually affects behavior, and the speed with which
such effects decay with time from epidemics, are matters for empirical
investigation.
One final determinant of vaccination behavior that is important for our
analysis is the perceived vaccine efficacy. Because the pneumococcal vaccine
primarily reduces pneumococcal disease such as bacteremia, but not the
pneumonia that causes most deaths after influenza complications (Centers for
Disease Control and Prevention 2003), fluctuations in influenza threat levels
should not affect pneumococcal vaccination demand. We hypothesize that
pneumococcal vaccination is responsive to influenza threat levels, however,
due to the common public misperception that this vaccine can reduce the
pneumonia complications arising from influenza.
In summary, the demand for vaccinations depends on the perceived risk
and severity of infection, perceived vaccine efficacy, health status, socio-
economic status, environmental factors, and vaccine costs. Based on the
conceptual framework, we posit three hypotheses regarding the effects of
disease threats on elderly vaccination behaviors.
H1: The influenza vaccination rate depends positively on the lagged
influenza threat.
H2: The pneumococcal vaccination rate also depends positively
on the lagged influenza threat, due to misperceptions of vaccine
efficacy.
H3: Threat-responsiveness behavior diminishes with the length of lag
since the threat.
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METHODS
Data
This study uses two different national datasets. The dependent variables——
individual-level influenza and pneumococcal vaccination status——and indivi-
dual-level explanatory variables are from the 1993 to 1998 Behavioral Risk
Factor Surveillance System survey data (BRFSS). The key explanatory
variables——the combined influenza and pneumonia mortality rates, which are
consistent with CDC reports——are measured from the Compressed Mortality
File. All of the key explanatory variables use data from 1990 to 1997 in order
to test the effect of lagged disease mortality, as discussed above. The study
population includes people aged 65 and older living in the community. There
are 38,768 individual observations in the final dataset.
The BRFSS is an ongoing data collection program to monitor state-level
prevalence of the major behavioral risks associated with premature morbidity
and mortality among adults. The CDC developed a core questionnaire for
states to collect data on actual behavior, rather than on attitudes or knowledge,
that would be especially useful for planning, initiating, supporting, and
evaluating health promotion and disease prevention programs. By 1994, all
states, the District of Columbia, and three territories were participating in the
BRFSS.
The BRFSS does not conduct the questionnaires of influenza and
pneumococcal vaccination on each state in every year. In 1993, 1995, and
1997, nearly all 50 states included the vaccination questions in the survey. In
1994, 1996, and 1998, however, only 9 states, 15 states, and 13 states in each
year, respectively, collected such vaccination information. This study
combines all of these six years’ data into one repeated cross-section dataset.
Robustness tests indicate that results do not significantly differ when the even
years with partial state participation are excluded. This is consistent with the
fact that states choose questionnaire modules years in advance, and thus there
is unlikely to be any systematic selection bias associated with whether a state
collects vaccination data in a given year.
Dependent Variables
This study evaluates two clinical preventive services by elderly persons——
influenza vaccination and pneumococcal vaccination. The outcome variables
are generated from the vaccination module in the BRFSS, which asks
respondents: ‘‘During the past 12 months, have you had a flu shot?’’ and
‘‘Have you ever had a pneumonia vaccination?’’ Two binary variables were
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created to indicate the influenza vaccination and pneumococcal vaccination
status for individual respondents for each year. During the study period, on
average, 60 percent of the respondents had received influenza vaccination in
the past year, and 39 percent of the respondents had ever had a pneumococcal
vaccination (Table 1). Both average vaccination rates are lower than the
Table 1: Summary Statistics for the Study Variables
Variables Mean Standard Deviation Minimum Maximum
Dependent Variables
Influenza vaccination .60 .49 0 1
Pneumococcal vaccination .39 .49 0 1
Explanatory Variables
State mortality (per 10,000) for both
influenza and pneumonia combined
3.29 .60 1.90 4.80
Individual characteristics
Age (splines) 71.15 3.22 65 74
65–74 2.28 3.45 0 10
75–84 .28 1.27 0 15
85 and older .35 .48 0 1
Male
Race
White non-Hispanic .90 .30 0 1
Black non-Hispanic .06 .24 0 1
Hispanic .02 .15 0 1
Other .02 .14 0 1
Education
No education or kindergarten .008 .089 0 1
Elementary .14 .35 0 1
Some high school .14 .35 0 1
High school graduate .34 .48 0 1
Some college or technical school .21 .41 0 1
College graduate .16 .36 0 1
Self-reported health status
Excellent .12 .33 0 1
Very good .25 .43 0 1
Good .33 .47 0 1
Fair .10 .29 0 1
Poor .20 .40 0 1
Living status
Numbers of extra adults at home in
addition to a spouse
.13 .43 0 8
Access to care
Cost problem of seeking needed care .05 .22 0 1
continued
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Healthy People 2000 goal of 65 percent of the elderly receiving the vaccination,
and far lower than the Healthy People 2010 goal of 90 percent.
Because of differences in wording between the influenza and
pneumococcal vaccine questions, magnitudes of effects on these dependent
variables will not be directly compared. The influenza question asks about the
annual vaccination rate, but the pneumococcal question asks about the
cumulative rate since only one pneumococcal vaccination is recommended
after age 65. Because the survey is a set of repeated cross-sections, rather than a
true panel, we cannot identify exactly which individuals received the
pneumococcal vaccination in the previous year. This is not a limitation for
our analyses, however, since we can still analyze whether the pneumococcal
vaccination rates increase in response to lagged influenza threat levels.
Interview Date Restriction
The timing of the survey recall period relative to the influenza season leads to a
further complication. The BRFSS survey asked respondents ‘‘During the past
12 months, have you had a flu shot?’’ During the past 19 influenza seasons in
the United States, the months with the heaviest influenza activity occurred in
December four times, in January five times, in February seven times, and in
March three times (Centers for Disease Control and Prevention 2002).
Table 1: Continued
Variables Mean Standard Deviation Minimum Maximum
Smoking status
Current smoker .19 .39 0 1
Former smoker .39 .49 0 1
Never a smoker .43 .49 0 1
Year
1993 .21 .41 0 1
1994 .05 .21 0 1
1995 .28 .45 0 1
1996 .10 .30 0 1
1997 .31 .46 0 1
1998 .05 .22 0 1
1. The data of the dependent variables and the individual characteristics are from 1993 to 1998 of
Behavioral Risk Factor Surveillance System.
2. State mortality rate is the overall average of county mortalities in each state, by different year,
from 1992 to 1997 of the Compressed Mortality File.
3. Years are dummy variables indicating from which data year each observation is drawn. The
mean values indicate the proportion of the study sample drawn from that specific year.
4. There are 38,768 observations.
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A respondent interviewed during the first quarter of 1995 would respond to two
different influenza seasons——the first quarter of 1994 and the fourth quarter of
1994. To evaluate the respondents’ vaccination behavior responding to a specific
single influenza season, this study restricts the sample to those interviewed in the
second and third quarters of each year. Similarly, Mullahy (1999) restricted his
sample to individuals responding to the survey in the first three quarters of
1991, but this would still allow people to answer questions about two influenza
seasons in the same survey. For consistency, we also use the second and third
quarter’s sample population for pneumococcal vaccination analysis.
Independent Variables
The key explanatory construct of interest is the influenza disease threat. There
are multiple potential ways to measure this threat. Because direct measures of
incidence and prevalence are incomplete at the required level of detail, we
have chosen an alternative measure that we argue yields the most precise
indicator of the actual threat in each state, the influenza and pneumonia
mortality rate. Although case fatality is low, the incidence rate is high, making
influenza and pneumonia leading causes of death for elderly. Furthermore,
both have a short infection period, and case-fatality does not differ greatly
from year to year. To the extent that case fatality does differ depending on the
adequacy of that year’s vaccine, this should vary uniformly nationwide, and
will not affect the appropriateness of using the state mortality rate as a proxy
for the state threat level in our analysis.
Following the standard practice in reports fromCDC, the cause-of-death
is measured as combined influenza (ICD-9Code: 487) and pneumonia (ICD-9
Codes: 480–486) together; this measure primarily reflects mortality from
influenza-related complications. The county-level cause-specific mortality
rates are derived from the National Center for Health Statistics’ Compressed
Mortality File, which includes data on deaths and population by county, age,
and underlying cause-of-death. These county mortality rates then are
combined to generate state average mortality rates, weighted by county
representativeness in our microdata from the BRFSS. From 1992 to 1997, the
average state mortality rate due to influenza and pneumonia was 3.29 per
10,000 population for all ages (range is from 1.90 to 4.80).
The individual characteristics in our empirical model include age,
gender, race, education, marital status, self-reported health status, living status,
access to care, and smoking behavior. The individual information comes from
the BRFSS, 1993 to 1998.
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Agemay have a nonlinear effect on the vaccination rate. Age is specified
as a piecewise linear function to generate three age groups——65–74, 75–84,
and 85 and older. About a third of the sample is male. The racial composition
is 90 percent white, 6 percent black non-Hispanic, 2 percent Hispanic, and 2
percent other race. Education levels are categorized fromno education or only
kindergarten to elementary, some high school, high school graduate, some
college or technical school, and college graduate. High school graduate is the
most common group (34 percent). Self-reported health status includes five
binary variables——excellent, very good, good, fair, and poor.Most of the study
sample reported to be in very good or good health status (total 58 percent).
However, 30 percent of the sample reported with fair or poor health status.
Elderly persons living with other people might be less interested in
receiving prevention because they might think they could get someone to take
care of them if needed, ormore interested because the risk of infectious disease
is larger when in close contact with more people. This factor may become
stronger when the elderly persons live with other adults in addition to their
spouses. Such co-residence may also decrease time costs. We generated a
variable equal to the number of adults at home in addition to spouses. The
range of this variable is from 0 to 8 and has mean of 0.13.
People with less access to the health care system are expected to receive
less prevention. We generated a dummy variable indicating whether the
respondent reported cost as a barrier to getting needed care in the past year (5
percent said ‘‘yes’’).
Smoking is both a proxy measurement of health prevention behavior,
and an indicator of susceptibility of illness. Current smokers are expected to be
less interested in health prevention services than nonsmokers. However,
current smokers may also be more vulnerable to respiratory disease, which
would increase their demand for vaccination. Binary variables were generated
to indicate current smoker (19 percent), former smoker (39 percent), and never
smoker (43 percent, the reference group).
BASIC MODEL
The basic model, developed in the conceptual framework section, models the
probability of vaccination as a function of the previous year’s state influenza
and pneumonia mortality rate and individual characteristics
Pr ðVaccinationÞ ¼ f ðlagged statemortality rate; individual characteristics;
unobserved individual and state factorsÞ
914 HSR: Health Services Research 39:4, Part I (August 2004)
The model is run separately for influenza and for pneumococcal vaccination.
Because the dependent variable is dichotomous, we estimate a logit model.
Lagged Information Approach and Fixed-Effects Model
Although we expect to find a positive correlation between the area mortality
rate and the vaccination rates, there are several econometric issues that
complicate this simple model. One potential problem is that the individual’s
vaccination status and cause-specific mortality rate may be determined
simultaneously. In order to avoid this potential endogeneity problem, we use a
lagged information approach to estimate vaccination status as a function of the
one-year laggedmortality rate. The individual characteristics are based on the
same years’ information as the dependent variables.
The main empirical model, therefore, is as follows
Vist ¼ b0 þ b1Mst1 þ b2Xi þ b3Yt þ b4Ss þ eist
where V is the individual propensity of vaccination utilization, M indicates
the state influenza and pneumonia mortality rate, X indicates a vector of
individual characteristics (e.g., age, gender, race, education, marital status,
health status, and health behavior), Y is a vector of year-specific dummies, S
is a vector of state fixed-effects dummy variables, and e is the error term. The
subscript i represents individual, s indicates state, t indicates the year, t 1
indicates the year prior to the observation of the dependent variables.
We first estimate a pooled cross-sectional model, omitting the fixed
effects by constraining b45 0. This is more efficient than the fixed-effects
model, but could lead to bias if there are omitted state variables such as norms
or access to care. Therefore, we also estimated a state fixed-effects model.
AHausman test rejected the null hypothesis of random effects in favor of fixed
effects for both vaccination analyses (po.01 for influenza vaccination, and
po.05 for pneumococcal vaccination). Finally, we reran the fixed-effects
models using increasing mortality lags of up to three years, in order to test the
rate at which the mortality-responsiveness declines.
RESULTS
The influenza vaccination rates and pneumococcal vaccination rates increased
nearly every year during the study period (Figure 1). Influenza vaccination
rates are higher than pneumococcal vaccination rates each year by about 20
percentage points. Unlike the vaccination rates, the mortality rates do not
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A. Vaccination Rates for Elderly Persons by Year.
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 Influenza and Pneumonia Mortality Rate, by Year
Figure 1: Trends of Vaccination Rates and Mortality Rates over Time
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show a steady trend. The mortality rate increased from 1992 to 1993, then
decreased in 1994. The rates were stable from 1994 to 1996 and decreased
again in 1997. The standard errors on these rates are extremely small,
implying that virtually all of the year-to-year changes are statistically
significant. However, the variation across states is quite large, with the
influenza and pneumococcal vaccination rates as high as 73 and 51 percent,
respectively, inWyoming and as low as 44 and 29 percent inWashingtonD.C.
Similarly, the mean influenza and pneumonia mortality rates in our sample
ranged from a high of 4.5 per 10,000 population in Massachusetts to a low of
2.3 per 10,000 population in Nevada. There are also substantial differences
across states in the year to year mortality changes. At the individual level, the
correlation between influenza and pneumococcal vaccination status is 0.42;
because the latter is a measure of lifetime rather than the previous year’s
vaccination, however, we do not attempt to further analyze the relationships
between these.
Cross-Sectional Analysis
In the pooled cross-sectional logit analyses, the mortality rate does not have a
significant effect on the probability of an elderly person receiving influenza
vaccination (see first column of Table 2). However, the mortality rates have a
significantly negative estimated effect on elderly person’s decision of receiving
pneumococcal vaccination (see third column of Table 2), which may suggest
misspecification due to omitted variables. This suspicion is corroborated by
Hausman tests, which reject random-effects models in favor of state fixed
effects, thus we next turn to the fixed-effects analysis.
Fixed-Effects Model
Our preferred model is the individual-level state fixed-effects regression that
also controls for individual characteristics. Higher state pneumonia and
influenza mortality rates induce more elderly persons to receive the
vaccinations (see columns 2 and 4 in Table 2). The result is significant for
the influenza vaccinationmodel but not the pneumococcal vaccinationmodel.
These findings support hypothesis one but do not support hypothesis two.
Marginal Effects of Mortality on Vaccinations
Another way to describe the effect of mortality on vaccinations is to calculate
the marginal effect of an increase in the combined influenza and pneumonia
mortality variable, defined as deaths per 10,000 population, based on the
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Table 2: The Effects of Mortality on the Probabilities of Receiving
Vaccination by Elderly Persons——Model Comparisons
Influenza Vaccination Pneumococcal Vaccination
Pooled Model State FE Model Pooled Model State FE Model
Constant –4.94nn –5.62nn  6.95nn –7.14nn
(.30) (.35) (.31) (.36)
Key Independent Variable
Mortality rate for influenza
and pneumonia
–.012 .120n –.060nn .048
(.020) (.049) (.020) (.048)
Control Variables
Age (splines)
65–74 .0710nn .0711nn .0864nn .0860nn
(.0041) (.0041) (.0043) (.0043)
75–84 –.0022 –.0028 –.0065 –.0067
(.0044) (.0044) (.0043) (.0043)
85 and older –.0368nn –.0369nn –.0445nn –.0442nn
(.0097) (.0097) (.0099) (.0099)
Male –.033 –.032 –.083nn –.083nn
(.023) (.024) (.024) (.024)
Race
Black non-Hispanic –.667nn –.626nn –.714nn –.697nn
(.045) (.047) (.052) (.054)
Hispanic –.158n –.175n –.350nn –.408nn
(.070) (.072) (.075) (.077)
Other nonwhite –.084 –.159 .118 –.051
(.077) (.088) (.077) (.089)
Education
None or kindergarten –.44nn –.46nn –.27n –.25
(.12) (.12) (.13) (.13)
Elementary –.305nn –.300nn –.285nn –.259nn
(.034) (.035) (.036) (.036)
Some high school –.115nn –.112nn –.098nn –.089nn
(.034) (.034) (.035) (.035)
Some college .160nn .149nn .195nn .176nn
(.030) (.030) (.030) (.030)
College .412nn .400nn .318nn .305nn
(.034) (.034) (.033) (.033)
Health Status
Excellent –.391nn –.396nn –.311nn –.319nn
(.035) (.036) (.037) (.037)
Very good –.119nn –.125nn –.087nn –.094nn
(.028) (.028) (.029) (.029)
Fair .315nn .324nn .428nn .448nn
(.041) (.041) (.040) (.040)
continued
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fixed-effects results. The marginal effect of an increase in mortality by 1 per
10,000 on influenza vaccinations, holding other factors constant, is 2.7
percentage points when averaged over the entire sample. To help interpret
this number, note that theCDC typically defines the influenza and pneumonia
epidemic threshold as 1.645 standard deviations above baseline (Brammer
et al. 2000). Given that the standard deviation of our mortality indicator is 0.6
(Table 1), a one-unit change in the mortality rate is equivalent to moving from
the baseline to an epidemic level. Alternatively interpreted, the estimated
elasticity is roughly .15. For pneumococcal vaccination the marginal effect of
mortality is 1.1 percentage points, yielding an estimated elasticity of roughly
Table 2: Continued
Influenza Vaccination Pneumococcal Vaccination
Pooled Model State FE Model Pooled Model State FE Model
Poor .152nn .156nn .210nn .218nn
(.031) (.031) (.030) (.031)
Extra adults at home –.173nn –.166nn –.128nn –.123nn
(.025) (.025) (.026) (.027)
Cost problem of care –.203nn –.211nn –.186nn –.190nn
(.049) (.049) (.052) (.052)
Smoking status
Current smoker –.208nn –.216nn .071n .057
(.034) (.035) (.035) (.036)
Former smoker .101nn .095nn .171nn .160nn
(.026) (.027) (.026) (.026)
Year
1994 .440nn .306nn .368nn .307nn
(.057) (.065) (.059) (.067)
1995 .429nn .408nn .497nn .464nn
(.034) (.035) (.036) (.037)
1996 .492nn .433nn .566nn .580nn
(.044) (.048) (.045) (.049)
1997 .676nn .666nn .831nn .818nn
(.033) (.034) (.035) (.035)
1998 .619nn .638nn .859nn .964nn
(.056) (.059) (.055) (.059)
1. Reference groups include: year 1993, female, white, high school graduate, good health status,
and nonsmoker.
2. n5% significance level,
nn1% significance level.
3. Coefficients for each state in the state fixed-effects models are not reported.
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.09; this magnitude should not be directly compared to the influenza marginal
effect because of the difference in question wording, but in any case this is not
statistically different from zero.
Individual Characteristics
The individual characteristics in the fixed-effects model have very similar
signs and magnitudes as the control variables in the cross-sectional model.
This implies that the individual characteristics are largely uncorrelated with
the state fixed effects.
The individual characteristics in both the fixed-effects and cross-
sectional analyses are often statistically significant, and generally have the
expected sign (Table 2). The probability of vaccination increases with age for
those aged 65 to 74 (po.01 for both vaccinations), is roughly flat for those aged
75 to 84, and negative for those over age 85 (po.01 for both vaccinations).
Men are significantly less likely to receive pneumococcal vaccinations than
women (po.01). Compared towhites, AfricanAmerican andHispanic elderly
persons are significantly less likely to receive either vaccination (po.01).
African Americans are far less likely than whites to receive vaccinations.
Education is strongly positively associated with getting vaccinated.
Those in worse health are more likely to get vaccinated. Compared to
the elderly persons with self-reported good health status, elderly persons with
worse self-reported health status significantly increase the propensities to
receive the vaccinations. Conversely, elderly persons with self-reported very
good or excellent health status significantly reduce the probability of receiving
vaccinations (all health status indicators for both vaccinations have po.01).
The results are reasonable because elderly persons who are in worse health
status have more to gain from preventing a serious illness. They are also more
likely to visit physicians, who in turn may bemore likely to order vaccinations
among the ill; these factors may independently increase the probability of
vaccination, and this is one reason for including this variable as a control.
The number of extra adults at home in addition to a spouse is negatively
associated with both influenza vaccination and pneumococcal vaccination
(po.01). This variable may be correlated with unmeasured low socio-
economic status, because those who live with others are generally less well off.
Elderly persons who reported a problem with access to health care due to cost
were also significantly less likely to receive either of the vaccinations (both
with po.01). Even though the costs of influenza vaccination and pneumo-
coccal vaccination are fully covered byMedicare, the study results here imply
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that other cost factors associated with access to care (e.g., copayments for
physician visits) might still influence vaccination decisions.
Current smokers are significantly less likely to receive influenza
vaccination (po.01) compared to nonsmoking elderly persons. In contrast,
elderly persons who were former smokers but quit smoking now have
significantly higher propensities of receiving influenza vaccination or
pneumococcal vaccination (both vaccinations with po.01) than nonsmoking
elderly persons.
Higher-Order Mortality Lags
To examine how quickly the effects of lagged mortality fade over time, we
replaced the one-year lagged mortality rate with either two-year or three-year
lags. The higher-order lags have substantially smaller effects than the one-year
lag, and are not statistically significant (Table 3). A final specification includes
all three lags in a single model, again confirming that only the one-year lag is
significant (for influenza), and the two-year and three-year lags have smaller
estimated effects. These results support our third hypothesis, that lagged
disease threat should have a declining effect on the vaccination rate.
DISCUSSION
Our study has produced a number of interesting policy-relevant and
methodological findings. Most important is our finding in support of the
threat-responsiveness hypothesis. Highermortality rates, which indicate more
severe disease threats, induce people to change their behavior and get
Table 3: Fixed-Effects Vaccination Logits withHigher-OrderMortality Lags
Influenza Vaccination Pneumococcal Vaccination
Pneumonia and
Influenza Mortality
1-Year Lag .120n .113n .048 .052
(.049) (.052) (.048) (.052)
2-Year Lag .063 .009 .008 –.016
(.051) (.057) (.051) (.057)
3-Year Lag .053 .037 .016 .014
(.050) (.052) (.049) (.051)
1. Control variables include all other variables in Table 2 regressions.
2. n5% significance level, nn1% significance level.
3. Coefficients for each state in the state fixed-effects models are not reported.
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vaccinated, albeit with a lag. A greater perceived health threat leads to greater
preventive behavior.
Second, the magnitude of the effect is modest, at least at mortality levels
found in our data. For example, an elasticity of .15 for influenza vaccination
implies that a 10 percent increase in last year’s influenza and pneumonia
mortality rate will lead to a 1.5 percent increase in this year’s vaccination rate.
Or alternatively stated, movement from baseline to epidemic thresholds only
leads to a 2.7 percentage point increase in the influenza vaccination level.With
amean influenza vaccination rate of 60 percent, an extremely severe epidemic
would be required before these self-limiting behavioral responses would have
much effect. A potential limitation of our analysis that might lead to
underestimated effects would be measurement error in the state mortality rate
as our proxy for individual’s information regarding epidemic severity. This
should be a good proxy given that public information campaigns often rely on
such aggregated epidemic surveillance, but future research will be required to
better understand the determinants of epidemic level perceptions.
Third, we foundmixed evidence on the role of (mis)perceptions. Threat-
responsiveness appeared to occur even after a one-year lag following the end
of the threat, but this effect had disappeared by the second year. Furthermore,
higher influenza threats did not lead to significantly higher pneumococcal
vaccination rates, as we had predicted would occur due to misperceptions.
This lack of a relationship, despite the positive influenza effects, is intriguing
because it also suggests that the extra health care contacts to receive the
influenza vaccine were not exploited to improve pneumococcal vaccination
rates. Although clinical practice guidelines do not recommend that physicians
increase pneumococcal vaccination efforts in response to influenza epidemics,
they do recommend taking advantage of primary care visits to increase
pneumococcal vaccination levels. Given that many elderly in our data who
received the influenza vaccination (presumably in part because of heightened
awareness of vaccine preventable infectious disease) remained unvaccinated
against pneumococcal pneumonia, awareness campaigns highlighting these
missed opportunities may be effective at improving pneumococcal vaccina-
tion rates.
Finally, we also have produced important methodological findings. We
have found that panel data methods are useful to control for state fixed effects
that may be correlated with both the vaccination rate and the mortality rate,
and that failure to control for these effects would have lead to downward bias.
Specification tests suggest that simple cross-sectional models may be mis-
specified.
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Our results point to the importance of further study of how public health
interventions can exploit disease threat-responsive behavior to increase
vaccination rates and hence lower future influenza and pneumonia mortality.
What types of public information campaigns best inform the public about
current and future infectious disease risk, in a way that will induce behavioral
change? Three different standard approaches would include information
through the media, information through providers, and increasing access in
public venues. Any of these methods could remind people about recent
epidemics, warn about the coming influenza season, and remind about the
risks of having infectious disease. Our estimates of the rapid decay of lagged
effects, however, suggests that continual ongoing interventions may be
necessary in order to generate sustained behavioral changes.
This study has two important limitations. We do not have information
on exactly howmuch elderly persons know about the actual mortality rate, for
example from media, professional journals, workshops, Internet, friends, or
senior centers. The amount of information will vary with the mortality rate,
and by region. Our results inform how the actual mortality rate affects
vaccination behavior, whereas another study might focus more on the
effectiveness of particular kinds of information dissemination. Second, we do
not have information on the exact date when people received their
vaccinations. Fortunately, we have a large enough sample that we can limit
our sample to those interviewed in the second and third quarters, which will
minimize this potential bias.
An additional consideration is associated with the potential effects of
provider behavior on elderly vaccination behavior. In general, the effects of
disease mortality may have two major pathways to affect elderly vaccination
behavior. One pathway directly affects elderly persons, and the other pathway
indirectly affects the health care provider’s behavior. For the pathway that
goes through providers, health care providers may have better channels to
know the disease epidemic than the general public, and then health care
providers respond to it by encouraging more of their patients to receive cost-
effective prevention. Future research will be needed to determine to what
extent individual behavioral responses are driven by these provider
behavioral responses. In addition, it would be important to explore which
interventions would be most helpful in changing people’s prevention
behavior. Is it more cost-effective to invest in patient education activities
(e.g., media, public health education programs) or to invest in professional
adherence activities (e.g., clinical guidelines, performance evaluation)? A
future analysis of this critical question would be valuable.
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